Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued.

摘要: L-Dopa supplemented by a peripheral decarboxylase inhibitor is considered the most potent therapeutic regimen prolonging active life in Parkinsonian patients. The long-term benefit of therapy limited adverse effects, such as dyskinesia and on-off phenomena, which can be mitigated concomitant administration dopamine agonists, bromocriptine. In order to quantify beneficial impact early combination therapy, controlled clinical trial (PRADO:PRA vi-del1 +DOpa) patients with Parkinson's disease was carried out, whereby monotherapy (in fixed benserazide (DoBe) being compared same plus bromocriptine (DoBeBro). Patients were recruited treated 101 practising neurologists Federal Republic Germany Hungary. 'Twenty seven university centers cross-checked at regular intervals. started 3 months DoBe (median dose 375 mg for both randomized groups) followed gradual substitution over one groups (250 L-Dopa/10 bromocriptine). target medication maintained from study 6 54.